Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 8,248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Clear all
Not listed Phase 1 Interventional

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

NCT04712864
View directory record Official record
Conditions
T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Recurrent, Peripheral T-Cell Lymphoma Recurrent
Interventions
LB1901
Biological
Lead sponsor
Legend Biotech USA Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Rochester, Minnesota • Houston, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Androgenetic Alopecia in Males and Females

NCT01437163
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
Device
Lead sponsor
Apira Science, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

NCT01791114
View directory record Official record
Conditions
Insulin Sensitivity, Obesity
Interventions
Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
Other
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 29, 2026, 4:32 PM EDT
Recruiting Phase 1 Interventional

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

NCT06384352
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Not applicable Interventional Results available

eHealth Partnered Evaluation Initiative - Evaluation of the Initial Deployment of VA's Annie Texting System

NCT03898349
View directory record Official record
Conditions
Hepatitis C
Interventions
Annie text messaging system, Annie text messaging system with Usual implementation, Annie text messaging system with Augmented implementation
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

NCT03961555
View directory record Official record
Conditions
Rabies
Interventions
SYN023, HRIG (HyperRab), Rabies vaccine
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • Milan, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 29, 2026, 4:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Administration Intravenous Treatment for Influenza

NCT01375985
View directory record Official record
Conditions
Influenza
Interventions
AVI-7100, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 29, 2026, 4:32 PM EDT
Terminated Early Phase 1 Interventional

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT04559685
View directory record Official record
Conditions
High Grade Glioma
Interventions
SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS), MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product · Device
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 29, 2026, 4:32 PM EDT
Not yet recruiting Early Phase 1 Interventional

Causal Mechanisms of Odor-Guided Behavior in Humans

NCT07099092
View directory record Official record
Conditions
Normal Physiology
Interventions
TUS PirC, TUS Amy, TUS Sham
Device
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl TDSs in Healthy Adults

NCT02486016
View directory record Official record
Conditions
Peer Review, Research
Interventions
Duragesic reference fentanyl TDS, Apotex generic fentanyl TDS, Mylan generic fentanyl TDS
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 1 Interventional

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

NCT04006704
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
6 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen

NCT00035633
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 29, 2026, 4:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

NCT06934538
View directory record Official record
Conditions
Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
Interventions
STC-1010 + IS regimen + SOC therapy
Biological
Lead sponsor
Brenus Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 4:32 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome

NCT07600658
View directory record Official record
Conditions
CACNA1C
Interventions
TS1-ASO
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Months and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 29, 2026, 4:32 PM EDT
Terminated Phase 2 Interventional Results available

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

NCT05211284
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure

NCT00052026
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol, placebo
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2008 · Synced Oct 29, 2026, 4:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Activity in Time Discrimination and Sensory Input

NCT00726050
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 4:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oocyte Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.

NCT00716118
View directory record Official record
Conditions
Infertility
Interventions
Not listed
Lead sponsor
West Coast Fertility Centers
Other
Eligibility
21 Years to 37 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 4:32 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

NCT04960397
View directory record Official record
Conditions
H3N2 Influenza
Interventions
Placebo, Sing2016 M2SR H3N2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

NCT02536313
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

NCT01519960
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 29, 2026, 4:32 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

NCT00432510
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
San Diego, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 29, 2026, 4:32 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial

NCT03429413
View directory record Official record
Conditions
Human Papillomavirus (HPV) Vaccines
Interventions
Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
1,296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 4:32 PM EDT